Amgen completes $3.7B acquisition of ChemoCentryx, adding TAVNEOS to portfolio

AMGEN INC

Acquisition closed at $52 per share in cash, aggregate consideration ~$3.7 billion.
Adds TAVNEOS (avacopan), a first-in-class oral therapy for severe active ANCA-associated vasculitis.
Also includes three early-stage drug candidates targeting chemoattractant receptors and an oral checkpoint for cancer.
TAVNEOS approved by FDA in Oct 2021; being studied in hidradenitis suppurativa and C3 glomerulopathy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.